Most Recent Articles by Marc Iskowitz
Could Kardashian West's now-notorious Diclegis social post be more than an OPDP case study?
Taking a look back at what's happened—and what hasn't happened—on the healthcare communications policy front so far this summer
From the 21st Century Cures Act to Amarin's off-label suit, Marc Iskowitz asks seven experts what the confluence of policy developments means for pharma promotion.
Last year's increase in CME support from manufacturers came after six straight years of declining budgets.
Can agencies prove that regulations no longer hinder Grand Prix-level branded work?
More Articles by Marc Iskowitz
Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.